Immuno-Oncology Biomarkers 2010 and Beyond

September 30, 2010
Masur Auditorium on the NIH Campus
Bethesda, MD

Program Schedule
To view slides from a presenter click the icon next to the presentation title.

Thursday, September 30, 2010 
8:00 am - 8:05 am Welcome and Introduction
Francesco Marincola, MD - National Institutes of Health (CC, DTM)
8:05 am - 8:20 am Presentation SlidesDefining the Critical Hurdles in Cancer Immunotherapy
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
8:20 am - 8:30 am Priorities in Biomarkers Development in Immunotherapy
Samir N. Khleif, MD – Vaccine Branch NCI, NIH
8:30 am - 9:45 am Session 1: Immunologic Monitoring: Standardization and Validation of Assays
Chair: Lisa H. Butterfield, PhD - University of Pittsburgh

Presentation SlidesRecommendations from the iSBTc/FDA/NCI Workshop on Immunotherapy Biomarkers
Lisa H. Butterfield, PhD – University of Pittsburgh

Presentation SlidesCTL on ELISPOT Standardization, Story of Successful Standardization
Paul V. Lehmann, MD, PhD – Cellular Technology Limited

Presentation SlidesHarmonization of Immunologic Monitoring Across Institutions
Cedrik M. Britten, MD – Association for Cancer Immunotherapy (CIMT)

Panel Discussion
Panelists: Session 1 Speakers: Sylvia Janetzki, MD - ZellNet Consulting, Inc. and Cancer Immunotherapy Consortium; and Michael Kalos, PhD - University of Pennsylvania
10:00 am - 12:00 pm Session 2: Correlation of Immunity to Clinical Response and Potency Assays

Chair:  Mary L. (Nora) Disis, MD - University of Washington

Presentation SlidesRegulatory and Scientific Considerations for Potency Testing and Immune Monitoring
Raj K. Puri, MD, PhD – U.S. Food and Drug Administration (CBER)

Presentation SlidesImmunologic Biomarkers as Correlates for Clinical Response
Mary L. (Nora) Disis, MD – University of Washington

Presentation SlidesMeasuring the Potency of Dendritic Cell Preparations Using Transcriptional Analysis
David Stroncek, MD – National Institutes of Health

Presentation SlidesSipuleucel-T Immune Parameters and Correlation with Overall Survival
Mark W. Frohlich, MD – Dendreon Corporation

Panel Discussion
Panelists: Session 2 Speakers; Leif Håkansson, MD, PhD - Biotherapy Development Association; and Nicholas P. Restifo, MD - National Cancer Institute
1:15 pm - 3:00 pm Session 3: Novel Methodologies for Assessing the Immune Landscape: Clinical Utility of Novel Technologies

Co-Chairs:  Francesco Marincola, MD - National Institutes of Health (CC, DTM)
             Peter P. Lee, MD - Stanford University

Presentation SlidesGenetic Variants in IL28B (IFN-λ): Major Predictors of Response to IFN-alfa Therapy for Chronic Hepatitis C
Thomas R. O’Brien, MD – National Cancer Institute, Division of Cancer Epidemiology and Genetics

A Critical Concentration of Cytolytically Active, Tumor Antigen-Specific CD8+T-Cells Is Required to Control Growth of Cognate Antigen-Expressing Tumor Cells In Vitro and In Vivo
Samuel C. Silverstein, MD – Columbia University

Immune Biomarkers: A Novel Paradigm for Cancer
Jérôme Galon, PhD – INSERM, Integrative Cancer Immunology Laboratory, Cordeliers Research Center

Presentation SlidesImmune Changes in Tumor-Draining Lymph Nodes as Novel Biomarkers
Peter P. Lee, MD – Stanford University

Panel Discussion
Panelists: Session 3 Speakers; Co-Chairs and Aniruddha (Raja) Choudhury, PhD Nordic Center for Development of Antitumor Vaccines, NCV-network
3:15 pm - 4:45 pm Session 4: Recommendations on Incorporation of Biomarkers into the Clinical Arena
Chair:  John M. Kirkwood, MD - University of Pittsburgh Cancer Institute

Presentation SlidesSingle Cell Network Profiling Technology and Applications in Immunological Monitoring
Diane Longo, PhD – Nodality Inc.

Presentation SlidesBiostatistical Considerations: Biologics and Biomarkers in Oncology
Daniel Normolle, PhD – University of Pittsburgh Cancer Institute

Presentation SlidesProspects for New Clinical Flow Cytometry Assays
Holden T. Maecker, PhD – Stanford University Medical Center

Presentation SlidesPredictive Biomarkers for Tumor Immunotherapy: Are We Ready for Clinical Implementation?
Howard L. Kaufman, MD, FACS – Rush University Medical Center
4:45 pm - 5:00 pm Summary and Conclusions of the Biomarkers Symposium
Lisa H. Butterfield, PhD - University of Pittsburgh
   
Friday, October 1
8:00 am - 5:00 pm Workshop on Monoclonal Antibodies in Cancer
For more information, please click here.
8:00 am - 5:00 pm Primer on Tumor Immunology and Biological Therapy of Cancer
For more information, please click here.
 
Saturday, October 2 - Monday, October 4
    iSBTc 25th Annual Meeting
   For more information, please click here

  

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.